Rxsight, Inc. 8-K Filing
Ticker: RXST · Form: 8-K · Filed: Dec 22, 2025 · CIK: 1111485
| Field | Detail |
|---|---|
| Company | Rxsight, Inc. (RXST) |
| Form Type | 8-K |
| Filed Date | Dec 22, 2025 |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $15,000, $500 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Rxsight, Inc. (ticker: RXST) to the SEC on Dec 22, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ich registered Common Stock, par value $0.001 per share RXST The Nasdaq Stock Mar); $15,000 (ill be paid non-refundable retainers of $15,000 for each of January, February and March); $500 (nen will also be paid an hourly rate of $500 for her services to the Company under t).
How long is this filing?
Rxsight, Inc.'s 8-K filing is 3 pages with approximately 834 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 834 words · 3 min read · ~3 pages · Grade level 10.3 · Accepted 2025-12-22 17:15:12
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share RXST The Nasdaq Stock Mar
- $15,000 — ill be paid non-refundable retainers of $15,000 for each of January, February and March
- $500 — nen will also be paid an hourly rate of $500 for her services to the Company under t
Filing Documents
- d19913d8k.htm (8-K) — 27KB
- d19913dex991.htm (EX-99.1) — 5KB
- g19913dsp1.jpg (GRAPHIC) — 2KB
- 0001193125-25-328951.txt ( ) — 145KB
- rxst-20251216.xsd (EX-101.SCH) — 3KB
- rxst-20251216_lab.xml (EX-101.LAB) — 17KB
- rxst-20251216_pre.xml (EX-101.PRE) — 11KB
- d19913d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. RxSight, Inc. Date: December 22, 2025 By: /s/ Ron Kurtz, M.D. Ron Kurtz, M.D. Chief Executive Officer and President